CAJ | 학술논문

目的：观察瑞舒伐他汀对轻中度高血压伴高脂血症患者炎性因子及踝臂指数的影响。方法将100例轻中度高血压伴高脂血症患者随机分为普伐他汀组和瑞舒伐他汀组,分别口服普伐他汀10 mg,每晚1次；瑞舒伐他汀5 mg,每晚1次；疗程8周,观测患者治疗前后的各项血脂指标、超敏 C 反应蛋白(hs-CRP)及踝臂指数(ABI)的变化。结果两组治疗前各项指标比较差异无统计学意义；与普伐他汀组比较,瑞舒伐他汀组治疗后总胆固醇(TC)、低密度脂蛋白(LDL-C)、hs-CRP 降低,ABI 增高(P <0.05)；与治疗前比较,治疗后瑞舒伐他汀组 TC、LDL-C、hs-CRP降低(P <0.05)。结论瑞舒伐他汀可明显降低轻中度高血压伴高脂血症患者各项血脂指标及 hs-CRP 水平,减轻血管炎性反应,并且明显改善患者的动脉弹性功能。
목적：관찰서서벌타정대경중도고혈압반고지혈증환자염성인자급과비지수적영향。방법장100례경중도고혈압반고지혈증환자수궤분위보벌타정조화서서벌타정조,분별구복보벌타정10 mg,매만1차；서서벌타정5 mg,매만1차；료정8주,관측환자치료전후적각항혈지지표、초민 C 반응단백(hs-CRP)급과비지수(ABI)적변화。결과량조치료전각항지표비교차이무통계학의의；여보벌타정조비교,서서벌타정조치료후총담고순(TC)、저밀도지단백(LDL-C)、hs-CRP 강저,ABI 증고(P <0.05)；여치료전비교,치료후서서벌타정조 TC、LDL-C、hs-CRP강저(P <0.05)。결론서서벌타정가명현강저경중도고혈압반고지혈증환자각항혈지지표급 hs-CRP 수평,감경혈관염성반응,병차명현개선환자적동맥탄성공능。
ABSTRACT:Objective To observe the clinical effect of rosuvastatin on inflammatory cytokines and ankle-brachial index (ABI)in mild-moderate hypertensive patients with hyperlipidemia.Methods A total of 100 mild-moderate hypertensive subjects with hyperlipidemia were randomly divided into two groups: pravastatin group (n = 50, pravastatin 10 mg,qn)and rosuvastatin group(n =50,rosuvastatin 5 mg,qn).All the subjects were observed for eight weeks.The blood lipid indexes,high sensitivity C-reactive protein (hs-CRP)and ABI were measured before and after treatment.Results Before treatment,there were no significant difference in the indexes between two groups. After treatment,ABI was significantly increased,the total cholesterol (TC),low-density lipoprotein (LDL-C)and hs-CRP were significantly decreased in pravastatin group as compared with rosuvastatin group (P <0.05).TC,LDL-C and hs-CRP in rosuvastatin group were significantly lower after treatment (P < 0.05 ).Conclusion Rosuvastatin could significantly reduce lipid parameters and hs-CRP levels in mild-moderate hypertensive patients with hyperlipidemia,alleviate the vascular inflammation and improve arterial elasticity function obviously.